Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma
Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma
复制标题
DOI：
10.1111/j.1872-034x.2010.00729.x
复制
发表时间：
2010-12-01
影响因子：
4.2
通讯作者：
Chayama, Kazuaki
中科院分区：
文献类型：
--
作者：
Katamura, Yoshio;Aikata, Hiroshi;Chayama, Kazuaki
目的：我们进行了一项回顾性队列研究，探讨放疗（RT）和唑来膦酸联合治疗对肝细胞癌（HCC）骨转移的疗效。此外，我们还研究了唑来膦酸对未照射骨转移的疗效。方法：本研究由 31 名因骨转移接受放疗的患者组成。其中 12 名具有 23 个骨转移部位的患者也接受了唑来膦酸治疗（Z 组）。在 Z 组中，14 个位点接受了 RT，9 个位点没有。 19 例 38 个骨转移部位的患者未接受唑来膦酸治疗（非 Z 组）。在非 Z 组中，22 个位点接受了 RT，16 个位点没有接受 RT。我们比较了各组之间的生存率、疼痛反应、疼痛进展时间、放射学反应、放射学进展时间和安全性。结果：虽然两组之间的疼痛反应率相似，但照射和未照射骨转移的疼痛进展时间在 Z 组中（6 个月时分别为 0% 和 20%）显着低于非 Z 组（6 个月时分别为 34% 和 66%）（P = 0.045 和 P = 0.005）。此外，虽然两组之间的放射学反应率相似，但 Z 组中未照射骨转移的放射学进展率（3 个月时为 29%）显着低于非 Z 组（3 个月时为 91%）（P = 0.009）。没有记录到明显的副作用。结论：唑来膦酸延缓了放射和未放射骨转移的疼痛进展以及 HCC 未放射骨转移的放射学进展。
Aim:We conducted a retrospective cohort study to investigate the efficacy of combination therapy with radiotherapy (RT) and zoledronic acid for bone metastases from hepatocellular carcinoma (HCC). Additionally, we investigated the efficacy of zoledronic acid for non-irradiated bone metastases.Methods:This study consisted of 31 patients who had received RT for bone metastases. Twelve of these patients with 23 sites of bone metastases were also treated with zoledronic acid (Z group). In the Z group, 14 sites received RT and nine sites did not. Nineteen patients with 38 sites of bone metastases were not treated with zoledronic acid (non-Z group). In the non-Z group, 22 sites received RT and 16 did not. We compared survival, pain response, time to pain progression, radiographic response, time to radiographic progression, and safety between groups.Results:While pain response rates were similar between the two groups, time to pain progression rates of irradiated and non-irradiated bone metastases was significantly lower in the Z (0% and 20% at 6 months, respectively) than in the non-Z group (34% and 66% at 6 months, respectively) (P = 0.045 and P = 0.005). Further, while radiographic response rates were similar between the two groups, time to radiographic progression rate of non-irradiated bone metastases was significantly lower in the Z (29% at 3 months) than in the non-Z group (91% at 3 months) (P = 0.009). No significant side-effects were documented.Conclusion:Zoledronic acid delayed the pain progression of both irradiated and non-irradiated bone metastases and the radiographic progression of non-irradiated bone metastases from HCC.